Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | The potential of ctDNA in oncology

Javier Garcia-Corbacho • 13 Oct 2021
ESMO 2021
General

Javier Garcia-Corbacho, MD, Hospital Clinic Barcelona, Barcelona, Spain, outlines the potential of circulating tumor DNA (ctDNA) for diagnosis and for monitoring response to treatment and disease evolution and predicts that it will soon be used in standard clinical practice. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Disclosures

Dr Garcia-Corbacho declares participation in multiple clinical trials and meetings as speaker (advisory role) and financial sponsor support for meeting attendance.

More from Javier Garcia-Corbacho

CLIMB360: ctDNA-based molecular screening
1:33
CLIMB360: ctDNA-based molecular screening
Javier Garcia-Corbacho • 13 Sep 2021

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026
The content of VJOncology is intended for healthcare professionals